AIM:To compare the efficacy of single-session 360-degree selective laser trabeculoplasty(SLT) for reduction of intraocular pressure(IOP) in patients with pseudoexfoliative glaucoma(PXFG) and primary open angle glaucom...AIM:To compare the efficacy of single-session 360-degree selective laser trabeculoplasty(SLT) for reduction of intraocular pressure(IOP) in patients with pseudoexfoliative glaucoma(PXFG) and primary open angle glaucoma(POAG).· METHODS:This is a single-center,prospective,nonrandomized comparative study.Patients older than 18 years of age with uncontrolled PXFG or POAG eyes requiring additional therapy while on maximally tolerated IOP-lowering medications were included.The primary outcome measure changed in IOP from baseline.Success was defined as IOP reduction ≥20%from baseline without any additional IOP-lowering medication.All patients were examined at 1d,1wk,1,3,6,9,12 mo after SLT.· RESULTS:Nineteen patients(20 eyes) with PXFG and27 patients(28 eyes) with POAG were included in the study.In the visual fields mean deviation was-2.88(±1.67)in the POAG and-3.1(±1.69) in the PXFG groups(P=0.3).The mean(±SD) IOP was 22.9(±3.7) mm Hg in the POAG group and 25.7(±4.4) mm Hg in the PXFG group at baseline and decreased to 18.4(±3.2) and 18.0(±3.9) mm Hg in the POAG group(P<0.001 and P=0.02),and to 17.9(±4.0) and 21.0(±6.6) mm Hg in the PXFG group(P<0.001 and P=0.47) at 6 and 12 mo,respectively.The number of medications was 2.6(±0.8) in the POAG group and 2.5(±0.8) in the PXFG group at baseline,and did not change at all follow-up visits in both groups(P =0.16 in POAG and 0.57 in PXFG).Based on Kaplan-Meier survival analysis,the success rate was 75%in the POAG group compared to 94.1%in the PXFG group(P=0.08;Log-rank test) at 6mo,and 29.1%and 25.0%at 12 mo,respectively(P=0.9;Log-rank).· CONCLUSION:The 360-degree SLT is an effective and well-tolerated therapeutic modality in patients with POAG and PXFG by reducing IOP without any change in number of medications.The response was more pronounced early in the postoperative period in patients with PXFG whereas there was no statistically significant difference at 12-month follow-up.展开更多
文摘AIM:To compare the efficacy of single-session 360-degree selective laser trabeculoplasty(SLT) for reduction of intraocular pressure(IOP) in patients with pseudoexfoliative glaucoma(PXFG) and primary open angle glaucoma(POAG).· METHODS:This is a single-center,prospective,nonrandomized comparative study.Patients older than 18 years of age with uncontrolled PXFG or POAG eyes requiring additional therapy while on maximally tolerated IOP-lowering medications were included.The primary outcome measure changed in IOP from baseline.Success was defined as IOP reduction ≥20%from baseline without any additional IOP-lowering medication.All patients were examined at 1d,1wk,1,3,6,9,12 mo after SLT.· RESULTS:Nineteen patients(20 eyes) with PXFG and27 patients(28 eyes) with POAG were included in the study.In the visual fields mean deviation was-2.88(±1.67)in the POAG and-3.1(±1.69) in the PXFG groups(P=0.3).The mean(±SD) IOP was 22.9(±3.7) mm Hg in the POAG group and 25.7(±4.4) mm Hg in the PXFG group at baseline and decreased to 18.4(±3.2) and 18.0(±3.9) mm Hg in the POAG group(P<0.001 and P=0.02),and to 17.9(±4.0) and 21.0(±6.6) mm Hg in the PXFG group(P<0.001 and P=0.47) at 6 and 12 mo,respectively.The number of medications was 2.6(±0.8) in the POAG group and 2.5(±0.8) in the PXFG group at baseline,and did not change at all follow-up visits in both groups(P =0.16 in POAG and 0.57 in PXFG).Based on Kaplan-Meier survival analysis,the success rate was 75%in the POAG group compared to 94.1%in the PXFG group(P=0.08;Log-rank test) at 6mo,and 29.1%and 25.0%at 12 mo,respectively(P=0.9;Log-rank).· CONCLUSION:The 360-degree SLT is an effective and well-tolerated therapeutic modality in patients with POAG and PXFG by reducing IOP without any change in number of medications.The response was more pronounced early in the postoperative period in patients with PXFG whereas there was no statistically significant difference at 12-month follow-up.
